CTOs on the Move

Immucor

www.immucor.com

 
For more than 30 years, Immucor has been a proud partner to thousands of hospitals, reference laboratories and donor centers. We remain focused on continuing to innovate as we work to advance the science of transfusion and transplantation diagnostics. We are guided by our corporate Mission and Values. We strive to create a world where anyone, anywhere in need of blood or an organ gets the right blood or organ that is safe, accessible and affordable. We will be guided by our Core Values of Respect, Integrity, Teamwork and Achievement. In doing so, we will: • strive to achieve the ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.immucor.com
  • 3130 Gateway Drive P.O. Box 5625
    Norcross, GA USA 30071
  • Phone: 770.441.2051

Executives

Name Title Contact Details

Similar Companies

NuGEN Technologies

NuGEN Technologies is a San Carlos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tech-Med Services

Tech-Med Services is a Hauppauge, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

D-Sharp Dental

D-Sharp Dental Inc. is a Burlington, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hermes Medical Solutions

Hermes Medical Solutions, Inc. is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Armetheon

Armetheon, Inc. is a privately held San Francisco Bay area-based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced biotech entrepreneurs and drug developers. Armetheon’s two late-stage small molecule drug candidates are for use in the areas of oral anti-coagulation and anti-arrhythmia for atrial fibrillation. The company was founded with the idea that drug innovations can happen by building on the success of proven medications. We create solutions that are within the same class of medication and that utilize the same mechanism of action as existing therapies. This development approach has the ability to offer peace of mind to patients while benefitting physicians, who may wish to reduce safety concerns, side effects and adverse events for their patients.